Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study

BACKGROUND: We evaluated immunogenicity of SCB-2019, a subunit vaccine candidate containing a pre-fusion trimeric form of the SARS-CoV-2 spike (S)-protein adjuvanted with CpG-1018/alum. METHODS: The phase 2/3, double-blind, randomized SPECTRA trial was conducted in five countries in participants age...

Descripción completa

Detalles Bibliográficos
Autores principales: Buntinx, Erik, Brochado, Leonardo, Borja-Tabora, Charissa, Yu, Charles Y., Alberto, Edison R, Montellano, May Emmeline B., Carlos, Josefina C., Toloza, Leonardo Bautista, Hites, Maya, Siber, George, Clemens, Ralf, Ambrosino, Donna, Qin, Haijing, Chen, Hui Ling, Han, Htay Htay, Hu, Branda, Li, Ping, Baccarini, Carmen, Smolenov, Igor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Clover Biopharmaceuticals. Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910015/
https://www.ncbi.nlm.nih.gov/pubmed/36781334
http://dx.doi.org/10.1016/j.vaccine.2023.02.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910015/
https://www.ncbi.nlm.nih.gov/pubmed/36781334
http://dx.doi.org/10.1016/j.vaccine.2023.02.017

Ejemplares similares